
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc has demonstrated robust financial performance, with total revenue growth of 84.7% year-over-year, primarily driven by a remarkable 117.2% increase in Genomics revenue, which reached $252.9 million. The company anticipates further revenue enhancement through higher average selling prices (ASPs) for its xF liquid biopsy assay and the xT CDx test, signaling a shift to more profitable products. Additionally, the expansion of its customer base via additional pharmaceutical contracts in its data and services business supports a positive long-term outlook for the company's financial trajectory.
Bears say
Tempus AI Inc's gross margins in the Data & Other segment decreased to 69.7% in Q3 from 76.8% in the previous year, indicating a concerning trend in profitability. The company has faced significant operational challenges, including a decline in operating cash flow by $168.5 million year-over-year and the presence of $518.8 million in debt, which raises concerns about its ongoing financial viability. Moreover, the risks surrounding lower-than-projected sales growth, regulatory hurdles, and the potential for declining reimbursement rates further exacerbate the already negative outlook for Tempus AI's stock.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares